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Background: Medication review with follow-up (MRF) is a service where community pharmacists undertake a medication review with 
monthly follow-up to provide continuing care. The ConSIGUE Program assessed the impact and implementation of MRF for aged 
polypharmacy patients in Spanish Community Pharmacies. The present paper reports on the clinical impact evaluation phase of 
ConSIGUE.  
Objective: The main objective of the study was to measure the effect of MRF on the primary outcome of the number of uncontrolled 
health problems. Secondary objectives were to analyze the drug-related problems (DRPs) identified as potential causes of ineffective 
or unsafe medications and the pharmacists’ interventions implemented during MRF provision.  
Methods: An open-label multi-centered cluster randomized study with comparison group (CG) was carried out in community 
pharmacies from 4 provinces in Spain during 6 months. The main inclusion criteria were patients over 64 years old, using 5 or more 
medicines. The intervention group (IG) received the MRF service (advanced medication review-type 3 MR) whereas patients in the CG 
received usual care.  
Results: 178 pharmacies recruited 1403 patients (IG= 688 patients; CG= 715 patients). During the 6 months of the study 72 patients 
were lost to follow up. The adjusted multi-level random effects models showed a significant reduction in the number of uncontrolled 
health problems over the periods in the IG (-0.72, 95% CI: -0.80, -0.65) and no change in the CG (-0.03, 95%CI: -0.10, 0.04). Main DRPs 
identified as potential causes of failures of uncontrolled health problems’ treatment were undertreated condition (559 DRPs; 35.81%), 
lack of treatment adherence (261 DRP; 16.67%) and risk of adverse effects (207 DRPs; 13.53%). Interventions performed by pharmacist 
to solve DRP mainly included the addition (246 interventions; 14.67%) and change (330 interventions; 19.68%) of a medicine and 
educational interventions on medicine adherence (231 interventions; 13.78%) and non-pharmacological interventions (369 
interventions; 22.01%).  
Conclusions: This study provides evidence of the impact of community pharmacist on clinical outcomes for aged patients. It suggests 
that the provision of an MRF in collaboration with general medical practitioners and patients contributes to the improvement of aged 
polypharmacy patients’ health status and reduces their problems related with the use of medicines. 
 
Keywords 
Medication Therapy Management; Community Pharmacy Services; Pharmacies; Pharmacists; Polypharmacy; Treatment Adherence and 
Compliance; Randomized Controlled Trials as Topic; Spain 
 
INTRODUCTION 
A high percentage of over 64-year-old patients have co-
morbidities and have multiple medications prescribed.1,2 
The ageing process involves both psychosocial and 
physiological changes that can have an influence on clinical 
outcomes.3 This population is reported to have a high 
prevalence of medicines’ overuse, administration errors 
and poor medication adherence.4 Age-related changes in 
pharmacokinetics and pharmacodynamics and inter-
individual variability in drug response increase the 
probability of interactions, contraindications and adverse 
effects.5 Aged patients are at a high risk of not achieving 
their pharmacotherapy goals and consequently, of 
presenting uncontrolled health problems despite being 
prescribed a high number of medications.6  
There is obvious need for systematic approaches to be 
adopted by health professionals to optimize medicines´ use 
and clinical outcomes in aged polypharmacy patients. The 
World Health Organization recommends implementing 
pharmacy services to monitor and individualize 
pharmacotherapy.
7
 A professional pharmacy service (PPS) 
is "a set of actions undertaken in or organized by a 
pharmacy, delivered by a pharmacist or other health 
practitioner, who applies their specialized health 
knowledge personally or via an intermediary, with a 
patient/client, population or other health professional, to 
optimize the process of care, with the aim to improve 
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health outcomes and the value of healthcare".8 There are a 
wide range of professional pharmacy services, from the 
simple provision of medicines information to more clinically 
complex such us medication review, disease state 
management and prescribing.9 A Medication Review with 
Follow up (MRF) is a professional service where community 
pharmacists collaborate with other members of the health 
care team and the patient to prevent and solve drug 
related problems (DRP) for the improvement of clinical 
outcomes.10 MRF healthcare plans include tailored 
interventions and a monitoring process to improve the 
level of control of health problems. The important 
philosophical and operational difference to the usual type 3 
or advanced medication review is that although not having 
access to medical records MRF has a protocol that includes 
a follow up over a period of time and is focused on clinical 
outcomes particularly control of the disease.11 
There is a continuing controversy around the effectiveness 
of PPS including medication reviews. Two recent overviews 
of the scientific literature found high and moderate 
strength of evidence for the positive effect of certain PPSs 
on reducing the number and improving the 
appropriateness of medicines, but limited evidence on 
clinical outcome indicators.12,13 The authors concluded that, 
since PPS are complex interventions, there was a need of 
carrying out studies with high internal validity that measure 
their short-term impact by means of surrogate clinical 
outcome variables, such as the control of health 
problems.12 On the other hand, studies with high external 
validity are also required to ensure positive outcomes in 
the later stage of service implementation in real practice. 
The Medical Research Council guidelines for the 
development and evaluation of complex interventions, 
recommends the use of cluster randomized designs, with 
both process and outcome assessment, to achieve not only 
effective but also reproducible services and interventions.14  
A national program was launched in Spain, called 
conSIGUE, to measure the clinical, economic and 
humanistic effectiveness of the MRF service on aged 
polypharmacy patients. This paper presents the results 
associated with the clinical impact of the service.  
The objectives were (1) to describe the effectiveness of 
MRF provision for aged polypharmacy patients on the 
number of uncontrolled health problems, (2) to identify 
DRPs potentially related to uncontrolled health problems 




Design and setting  
An open-label multi-centered cluster randomized 
controlled study was carried out in 178 volunteer 
community pharmacies from 4 provinces in Spain selected 
by the General Council of Spanish Pharmacist (Gipuzkoa, 
Granada, Las Palmas and Santa Cruz de Tenerife) during 
eight months (May 2012-Jan 2013). Pharmacies in the 
intervention group (IG) provided the MRF service whereas 
comparison group (CG) pharmacies provided usual care and 
received no support on the provision of MRF. The Consort 
statement to improve reporting of cluster randomized 
controlled trials and minimize the risk of bias was applied.15 
Patients 
Design of this study was previously tested in a one-month 
pilot study carried out in one Spanish province (Cádiz). 
Sample size was calculated based on the pilot data to 
detect a hypothesized reduction of 10% in the proportion 
of uncontrolled health problems in the IG compared to the 
CG, considering an alpha error of 0.05 with 80% power in a 
two-way bilateral contrast. According to this calculation, 
393 patients in each group would be required. Applying the 
standard criteria for cluster randomized trials, this initial 
sample size was multiplied by a design effect (DE) of 1.1854 
to have into account the clustering effect of randomization 
at pharmacy level. The DE was calculated as follows: 
 
The ICC in the present work (0.0206) was calculated from 
the pilot study, and the mean cluster size was assumed to 
be 10 patients.16 A 12% inflation was applied to prevent the 
possibility of unequal cluster sizes.17 In addition, a potential 
loss at follow-up of 20% was estimated. Therefore, a 
minimum of 1,230 aged polypharmacy patients were 
required. Local pharmacist associations offered all 
pharmacies within their area the voluntary participation on 
the program and those pharmacies that accepted were 
randomized into intervention and control group. Within 
each pharmacy, patients were selected by convenience 
sampling to facilitate the access to patients and their 
physicians, according to the following criteria: patients over 
64 years old, using five or more medicines for a period 
longer than six months and giving their informed consent 
to participate in the study.  
Intervention 
Pharmacies in the intervention group (IG) provided MRF 
during 6 months using the Dader method.10,11 The Dader 
method for MRF includes three stages: (1) Analysis of 
patients’ medication therapy: face to face patients’ 
interview to obtain information on their health problems 
and medicines, assessment of the pharmacotherapy to 
identify uncontrolled health problems as well as DRPs 
potentially related to pharmacotherapy failures. (2) Care 
plan: Interventions directed to the physician or to the 
patient to prevent or solve drug related problems and 
improve the level of control of health problems. 
Pharmacists-physician communication was agreed with the 
patient and it could have been both oral (by phone or face-
to-face) and written (a letter given to patients). (3) Follow 
up: Visits with the patient on a monthly basis for the 
assessment of interventions’ results and continuance with 
patients’ care plan. Further details of the intervention 
elements are provided in TiDier Checklist (available at the 
Online appendix).18 Pharmacists within the IG were trained 
both for data collection and for MRF provision. Before the 
beginning of the study, they received a 5-day off-site 
training program on service provision, pharmacotherapy 
issues in treating patients, disease state management, 
evidence-based practice, communication with the patient 
and with other health professionals, data collection and 
clinical cases. During service provision, they received on-
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site support by a practice change facilitator (monthly visits 
as well as weekly telephone and email contact). 
Pharmacists within the CG attended a course on data 
collection and did not receive any information on MRF 
service. 
Study outcomes 
Assessment of control of health problems: Documentation 
on clinical history, including disease and medication history, 
were provided by the patient. The number of uncontrolled 
health problems, classified by means of International 
Classification of Primary Care, was assessed based on the 
achievement or not of the desired therapeutic outcomes 
for each individual patient, in 6 different points in time (on 
monthly basis).19 A combination of three different 
assessment criteria were used by the pharmacist, 
depending on the nature of the health problem, under the 
supervision of the facilitator of practice change: (1) 
achievement of desired values of the clinical parameters of 
control based on clinical guidelines recommendations, (2) 
improvement or resolution of signs or symptoms based on 
clinical information provided by the patient (3) 
achievement of the desired prevention by means of the 
patients’ self-reported adherence to the treatment. Several 
covariables were collected: age, gender, education level, 
civil status, number of health problems, and the number of 
medicines at each study period. DRP identified by the 
pharmacist were recorded according to Foro agreement (a 
Spanish national committee of professional and university 
representative).10  
Statistical analysis 
Data analysis was performed using PASW v-18.0. P-values 
less than 0.05 (p<0.05) were interpreted as statistically 
significant. Clustered data were analyzed using a multilevel 
model that included repeated measures in 6 different 
points and accounted for the clustering effect of the 
randomization at the pharmacy level.15 The initial multi-
level random effects model for the outcome included all 
four nested levels (province, pharmacy, pharmacist and 
patient) and random effect for data collection point with an 
independent covariance structure. There were other 
independent variables collected on patients at 6 time-
points that were included in the multi-level random effects 
linear model to account for other factors that might explain 
the change in the outcome over time and its variability at 
any given time, using a stepped approach. An interaction 
term of intervention/comparison group and time-point was 
included to estimate the outcome at each time-point. To 
show the number of uncontrolled health problems (by 
study group) at each time-point, marginal means were 
estimated to explore if there were changes in the outcome 
over time and if these changes were different in the study 
groups accounting for other factors. 
Ethical considerations 
The study was approved by ‘Virgen de las Nieves Hospital 
Clinical Research Ethics Committee’. Patients gave 




178 pharmacies (250 pharmacists) initially recruited 1,403 
patients (IG=688 patients and CG=715 patients). Mean 
number of patients/pharmacies were 7.88 (SD=2.40). A 
total of 1,331 patients (94.9%) completed the study; 72 
patients were lost to follow up and excluded from the 
analysis (Figure 1).  
Socio-demographic characteristics of patients and baseline 
data are described in Table 1. Study groups presented 
statistically significant differences for the level of 
education, mean number of medicines, health problems 
and uncontrolled health problems. At baseline, a mean 
number of 4.65 (SD=1.66) conditions per patient were 
assessed by community pharmacists as controlled or 
uncontrolled using the mentioned assessment criteria and 
a mean number of 7.74 (SD=2.50) medicines per patient 
were studied by pharmacists in the IG to identify DRPs. 
Patients in the IG presented a significantly higher number 
of conditions (4.35 vs 4.96: p=0.001), uncontrolled health 
problems (1.46 vs 0.73: p<0.001) and medicines (7.39 vs 
7.74: p=0.009) compared to patients in the CG.  
Figure 1. Flow diagram of patients 
IG: intervention group; CG: comparison group 
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Effect of MRF on the number of uncontrolled health 
problems 
Over the 6 months of the study, there was a statistically 
significant reduction in the number of uncontrolled health 
problems in the IG (-0.81, 95%CI: -0.89, -0.73) while there 
was no significant change in the CG (-0.05, 95%CI: -0.1, 
0.0002).  
Figure 2 shows the prevalence of each type of uncontrolled 
health problems (International Classification of Primary 
Care) at baseline.19 The most frequent uncontrolled health 
conditions identified by pharmacists were, psychological 
problems (17.08% in the IG and 27.19% in the CG), 
musculoskeletal problems (16.09% in the IG and 14.83% in 
the CG) and general and unspecified conditions (10.33% in 
the IG and 16.92% in the CG). There were no statistically 
significant differences among the groups before the 
interventions for any of the categories of health problems, 
except for cardiovascular (p=0.007) and endocrine 
(p=0.001) conditions which were more prevalent in the IG.  
On accounting for the nested data collection in the multi-
level random effects model (Table 2), the patients in the IG 
had statistically significantly more uncontrolled health 
problems (mean difference 0.66, 95%CI: 0.51, 0.82) than 
the CG at baseline, which remained on adjustment for 
other factors (gender, partner status, education, number of 
patient drugs, quality of life). Marginal mean effects 
calculated by means of this model show the change in the 
difference in number of uncontrolled health problems 
between the two groups over the periods (Table 3). In the 
unadjusted model, there is no significant difference in the 
number of uncontrolled health problems between IC and 
CG by the end of the timeframe (mean difference at 6th 
month -0.06, 95%CI: -0.20, 0.09). There is a significant 
mean reduction over the 6 months in the IG of -0.76 health 
problems (95%CI: -0.83, -0.69) compared to a non-
significant reduction over the 6 months in the CG (-0.04, 
95%CI: -0.10, 0.03). This change was also obtained in the 
multilevel analysis performed to control for baseline 
differences between groups, age, gender, partner status, 
education, number of patient´s drugs, quality of life 
measured by validated tool EuroQol, as well as the number 
of emergency room visits and hospital admissions in the 
prior 6 months (Table 2). On accounting for these factors, a 









Age; mean (SD) 1403 74.92 (6.59) 75.34 (6.46) 0.243 
Gender: Female; n (%)  1396 441 (61.7) 409 (60.1) 0.535 
Partner Status: with partner; n (%)  1242 384 (59.3) 355 (59.8) 0.856 
Education; n (%) 1174   0.004 
No formal education  116 (18.7) 149 (27)  
Completed primary education  313 (50.3) 239 (43.3)  
Completed secondary education  135 (21.7) 106 (19.2)  
Completed university education  58 (9.3) 58 (10.5)  
Number of medicines; mean (SD) 1403 7.39 (2.37) 7.74 (2.50) 0.009 
Number of health problems  1403 4.35 (1.49) 4.96 (1.76) <0.001 
Number of uncontrolled health problems; median (IQR) 1403 0.73 (0.66-0.8) 1.46 (1.36-1.56) <0.001 
Figure 2. Type of baseline uncontrolled health problems in the IG and CG 
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significant reduction over the period in the IG (-0.72, 
95%CI: -0.80, -0.65) no change in the CG (-0.03, 95%CI: -
0.10, 0.04) and a mean difference between groups at 6th 
month of -0.04, (95% CI: -0.19, 0.11) were obtained.  
DRPs and pharmacists’ interventions performed during 
the provision of MRF 
During the six months of the study, pharmacists providing 
the MRF identified a total of 1,561 DRPs which were 
considered as potential causes of ineffective or unsafe 
medications of a total of 1,529 uncontrolled health 
problems’ treatment (Table 4). The most prevalent DRPs 
identified were, undertreated condition (559 DRPs; 
35.81%), lack of treatment adherence (261 DRP; 16.7%) 
and risk of adverse effects (207 DRPs; 13.26%).  
Pharmacists performed a total of 1,676 interventions in an 
attempt to solve the problems related to the use of 
medicines, a mean of 1.1 interventions per DRP (Table 5). 
The most frequent were the suggestion of adding a 
medicine (246 interventions; 14.67%) and medication 
substitution (330 interventions; 19.68%), as well as 
educational interventions on medicine adherence (231 
interventions; 13.78%) and non-pharmacological advices 
(369 interventions; 22.01%). Pharmacists interventions 
were directed to the patient (790 interventions; 47.13%), to 
the physician (750 interventions; 44.73%), and both the 
patient and the physician (136 interventions; 8.12%) and 




This study reports important evidence that may clarify 
some key aspects around the existing controversy on the 
effectiveness of MRF in aged polypharmacy patients’ 
clinical outcomes.12,13 To our knowledge, this is the first 
study using the control of health problems as a surrogate 
outcome indicator of PPS’s impact in the aged population. 
Its methodology combines several essential 
recommendations for the assessment of complex 
interventions.14 The detailed description of the intervention 
(TIDieR checklist) as well as the use of process indicators 
(DRPs) provides a reproducible intervention for other 
researchers and may contribute to a better understanding 
of the intervention. The use of a cluster-randomized 
controlled design allowed us to avoid contamination bias 
whereas the presence of a facilitator of practice change 
providing on-site support to pharmacists increased the 
quality of data collection, the fidelity of the intervention 
and decreased the assessment bias typical of non-blinded 
trials.  
Table 2. Associations with Number of uncontrolled health problems: Multilevel mixed-effects linear regression models* 
Variable; mean (95%CI) 
Number of uncontrolled health problems 
Univariate Multivariable 
Intervention vs Control group   
Difference between intervention and control groups at baseline 0.66 (0.51,0.82) 0.66 (0.5,0.81) 
Age   
Change per 10-year increase of age of patient at any given time-point -0.03 (-0.09,0.04) - 
Gender   
Difference in Men compared to Women at any given time-point -0.36 (-0.45,-0.28) -0.24 (-0.34,-0.14) 
Partner status   
Difference in those Without Partner compared to With Partner at any time-point 0.11 (0.01,0.2) -0.02 (-0.12,0.08) 
Education   
Difference in those with Primary Studies compared to No studies at any time-point -0.09 (-0.22,0.05) -0.01 (-0.14,0.11) 
Difference in those with Secondary Studies compared to No studies at any time-point -0.28 (-0.45,-0.12) -0.09 (-0.24,0.07) 
Difference in those with University Studies compared to No studies at any time-point -0.42 (-0.62,-0.23) -0.18 (-0.37,0.01) 
Number of patient's drugs   
Change per increase of number of drugs at any given time-point 0.11 (0.095,0.124) 0.09 (0.08,0.11) 
EQ5D Index Value   
Change per increase of 0.1 in EQ5D Index Value at any given time-point -0.06 (-0.067,-0.052) -0.04 (-0.05,-0.03) 
EQ5D VAS Scale   
Change per increase of 10 in EQ5D VAS scale at any given time-point -0.07 (-0.08,-0.06) -0.03 (-0.05,-0.02) 
Number of ER visits in the six months prior to baseline   
Change per increase in ER visit in 6 months prior to baseline, at any given time-point 0.01 (-0.02,0.05) -0.02 (-0.06,0.01) 
Number of hospital admissions in the six months prior to baseline   
Change per increase in Hospital Admissions in 6 months prior to baseline, at any given time-point -0.05 (-0.17,0.06) -0.08 (-0.21,0.06) 
Table 3. Number of uncontrolled health problems over time and difference between Intervention and Control Groups: Marginal Means predicted from 
multilevel mixed-effects linear regression models* 
Time 
period 
Univariate model Multivariable model 
Mean (95% CI) number of  
uncontrolled health problems 
Mean difference (95%CI) 
between IG and CG 
Mean (95%CI) number of 
uncontrolled health problems 
Mean difference (95% CI) 
between IG and CG 
Intervention Control Intervention Control 
Month 1 1.42 (1.16,1.68) 0.75 (0.49,1.01) 0.66 (0.51,0.82) 1.38 (1.15,1.6) 0.72 (0.5,0.94) 0.66 (0.5,0.81) 
Month 2 1.26 (1.01,1.52) 0.4 (0.49,1.00) 0.52 (0.38,0.66) 1.23 (1.01,1.45) 0.71 (0.5,0.93) 0.52 (0.37,0.67) 
Month 3 1.11 (0.86,1.37) 0.74 (0.48,0.99) 0.38 (0.23,0.52) 1.09 (0.87,1.31) 0.71 (0.49,0.92) 0.38 (0.24,0.52) 
Month 4 0.96 (0.7,1.22) 0.73 (0.47,0.98) 0.23 (0.09,0.37) 0.94 (0.73,1.16) 0.7 (0.49,0.92) 0.24 (0.1,0.38) 
Month 5 0.81 (0.55,1.06) 0.72 (0.47,0.98) 0.09 (-0.06,0.23) 0.8 (0.58,1.02) 0.7 (0.48,0.91) 0.1 (-0.04,0.25) 
Month 6 0.66 (0.4,0.91) 0.71 (0.46,0.97) -0.06 (-0.2,0.09) 0.65 (0.43,0.88) 0.69 (0.47,0.91) -0.04 (-0.19,0.11) 
*considering the variation over time and between Provinces, Pharmacy’s and Pharmacists. 
IG: intervention group; CG: control group; 95%CI: 95% confidence interval 
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Interestingly, our population had approximately 5 health 
problems and was using more than 7 medications on 
average, which suggests a high health care expenditure. 
However, they presented more than one uncontrolled 
health problem at baseline. These data reinforce the need 
of having a health care professional such as a pharmacist 
ensuring that medications are used in an effective and safe 
manner. MRF has as a key feature of the continuous 
assessment of patient clinical outcomes, which allows the 
pharmacist to propose interventions directed to the control 
of health problems.11 The main direct effect expected from 
MRF on patients´ clinical outcomes was a reduction of the 
number of these uncontrolled health problems. A 
systematic review had highlighted the paucity of studies 
which actually report on this clinical outcome.
20
 
Our results suggest that MRF has a beneficial impact in this 
clinical outcome indicator (significant reduction of 0.72 
uncontrolled health problems within 6 months). Baseline 
differences between groups (more complicated patients 
with a lower level of education in the IG) are commonly 
reported in the intervention groups of these types of 
studies and may be due to potential practice biases. It 
appears that since selection criteria were broad and 
pharmacist providing MRF had the flexibility to choose 
those patients, they chose more complicated patients. In 
future studies, there may be a need not only to cluster the 
pharmacies but to have a more systematic method of 
patient sampling. Nevertheless, the multilevel and 
multivariate analysis controls the potential effect of these 
confounding variables. Interestingly the change observed in 
the decline in number of uncontrolled health problems was 
progressive throughout the study periods; in period 6 the 
prevalence of uncontrolled health problems, initially higher 
in the IG than in the CG, was reversed. This time lag of the 
effect could be related to the chronic conditions of aged 
patients, which need longer periods to be controlled and 
therefore logically need a follow up. Our results are 
supported by Sorensen et al. who evaluated the effect of a 
6 month-medication review that included, as MRF does, 
physician–pharmacist collaboration and the monitoring of 
patients’ outcomes.21 They found a positive effect on the 
severity of illness as well as a reduction in frequency of 
adverse events.  
Measurement of the control of chronic health problems in 
primary care settings has many potential benefits for the 
management of polypharmacy aged patients however this 
concept is not well integrated in primary care setting 
routine activities for pharmacy. This study demonstrated 
the feasibility of measuring it in the daily clinical practice of 
a community pharmacy with our data indicating that there 
were 1,529 uncontrolled health problems. However, 
reliability of this clinical outcome variable constitutes an 
important challenge for community pharmacists. To 
enhance this key activity of the pharmacists, future studies 
should analyze this assessment procedure by using 
consensus techniques that include other professional views 
and further efforts should be done to enable pharmacists 
to monitor the most prevalent uncontrolled health 
problems, especially endocrine metabolic and nutritional 
problems, cardiovascular conditions and musculoskeletal 
problems. 














Total number of uncontrolled health problems with a DRP 349 (65.1%) 391 (83.0%) 274 (78.1%) 213 (74.7%) 197 (73.5%) 105 (58.7%) 
Wrong administration 21 (6%) 13 (3.3%) 10 (3.6%) 6 (2.8%) 3 (1.5%) 1 (1.0%) 
Individual characteristics 28 (8%) 44 (11.3%) 30 (10.9%) 24 (11.3%) 27 (13.7%) 12 (11.4%) 
Contraindication 2 (0.6%) 6 (1.5%) 5 (1.8%) 1 (0.5%) 1 (0.5%) - 
Wrong dose/ posology/lenght 40 (11.5%) 46 (11.8%) 29 (10.6%) 22 (10.3%) 17 (10.6%) 15 (14.3%) 
Duplicity 8 (2.3%) 8 (2.0%) 4 (1.5%) 3 (1.4%) 3(1.5%) 2 (1.9%) 
Wrong prescription 9 (2.6%) 9 (2.3%) 5 (1.8 %) 3 (1.4%) 4 (2.0%) 1 (1.0%) 
Non-adherence 77 (22.1%) 67 (17.1%) 37 (13.5%) 32 (15.0%) 29 (14.7%) 19 (18.1%) 
Interactions 9 (2.6%) 9 (2.3%) 8 (2.9%) 3 (1.4%) 3 (1.5%) 1 (1.0%) 
Not necessary drug 5 (1.4%) 3 (0.8%) 3 (1.1%) 1 (0.5%) 2 (1.0%) 2 (1.9%) 
Other conditions that affect the treatment 6 (1.7%) 11 (2.8%) 6 (2.2%) 4 (1.9%) 4 (2.0%) 4 (3.8%) 
Risk of adverse effects 45 (12.9%) 57 (14.6%) 34 (12.4%) 27 (12.7%) 30 (15.2%) 14 (13.3%) 
Undertreated condition 102 (29.2%) 130 (33.2%) 106 (38.7%) 94 (44.1%) 86 (43.7%) 41 (39.0%) 
Other DRPs 13 (3.7%) 10 (2.6%) 11 (4.0%) 9 (4.2%) 6 (3.0%) 3 (2.9%) 
DRP: drug related problem 














Proposal to general practitioner       
Dose modification 25 (7.1%) 34 (8.6%) 23 (8.3%) 18 (8.4%) 16 (8.1%) 8 (7.6%) 
Dosage modification 18 (5.1%) 21 (5.3%) 11 (4.0%) 8 (3.7%) 9 (4.6%) 4 (3.8%) 
Schedule modification 13 (3.7%) 13 (3.3%) 13 (4.7%) 6 (2.8%) 3 (1.5%) 1 (1.0%) 
Adding a medication 44 (12.5%) 52 (13.2%) 43 (15.6%) 46 (21.5%) 42 (21.3%) 19 (18.1%) 
Medication withdrawal 25 (7.1%) 33 (8.4%) 19 (6.9%) 9 (4.2%) 9 (4.6%) 5 (4.8%) 
Medication substitution 64 (18.2%) 77 (19.5%) 71 (25.7%) 47 (22%) 47 (23.9%) 24 (22.9%) 
Referral with no specific proposal 22 (6.3%) 20 (5.1%) 10 (3.6%) 16 (7.5%) 19 (9.6%) 14 (13.3%) 
Patient health education       
Use and medicine administration 29 (8.2%) 23 (5.8%) 16 (5.8 %) 9 (4.2%) 7 (3.6%) 7 (6.7%) 
Medication adherence 71 (20.2%) 57 (14.5%) 33 (12%) 28 (13.1%) 25 (12.7%) 17 (16.2%) 
Non-pharmacological advice 75 (21.3%) 103 (26.1%) 70 (25.4%) 53 (24.8%) 43 (21.8%) 25 (23.8%) 
Total number of interventions 365 413 339 229 215 115 
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Another difficulty of complex interventions assessment is 
to understand which part of the intervention contributed 
to the effects observed. The description of DRPs identified 
and interventions implemented across the six months 
provides important evidence about the potential to link 
them with the clinical impact. The more we understand the 
causes of lack of control of health problems, the more 
effective our interventions will be. In a recent study with 
community-dwelling aged patients a mean of 4.8 DRPs per 
patient were identified, a higher prevalence compared to 
our results, despite being a slightly younger population 
taking less medicines.22 The main reason for this difference 
is that pharmacists in our study have reported only those 
DRPs potentially related to uncontrolled health problems 
whereas most of the studies on DRPs do not distinguish 
between potential and real causes of medication failures. 
With this new approach pharmacists can address 
specifically those process indicators that may have a higher 
impact on patient´s clinical outcomes. These intervention 
and acceptance ratios are also like those obtained in the 
study of Rhalimi et al.23 
 
CONCLUSIONS 
This study provides evidence on the role of the pharmacist 
for aged patients’ clinical outcomes. It suggests that the 
addition of a skilled community pharmacist to the primary 
care team could contribute to the improvement of aged 
polypharmacy patients’ health status and to reduce their 
problems related with the use of medicines. MRF 
conducted by community pharmacists during 6 months 
significantly reduced the number of uncontrolled health 
problems of aged polypharmacy patients by means of 
identifying DRPs, performing educational interventions 
with patients, and proposing medication changes to 
general practitioners. Decision makers could use this 
evidence when designing the management strategies for 
polypharmacy patients, considering the inclusion of the 
pharmacist in the primary health care team to improve the 
efficiency of the health care system. 
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